Published: 2021-03-08

Page: 44-52


Department of Botany, University of Kashmir, Srinagar-190006, Jammu and Kashmir, India.


Department of Botany, University of Kashmir, Srinagar-190006, Jammu and Kashmir, India.


Department of Botany, University of Kashmir, Srinagar-190006, Jammu and Kashmir, India.


Department of Technical Education, IET, Lucknow, India.

*Author to whom correspondence should be addressed.


The pandemic declaration of Covid-19 infection by World Health Organization (WHO) and ensuing boundless morbidities and mortalities in practically all nations of the world prompted the innovative work to discover an immunization against SARS-CoV2 infection. Typically any new vaccine takes 10–15 y time. In pandemic circumstance, the whole cycle of vaccine development including clinical preliminaries gets shortened and optimized to 10–14 month time. i.e. the quest for vaccine against Covid-19 is going on at a high speed coming with the good news of two vaccines Covishield and Covaxin. This review aims at highlighting the present stages of development of vaccinesin Indian scenario.


Keywords: Coronavirus, covaxin, covishield, clinical, vaccines.

How to Cite

RATHER, R. A., ISLAM, T., REHMAN, I. U., & PANDEY, D. (2021). DEVELOPMENT OF VACCINE AGAINST CORONAVIRUS DISEASE 2019 (COVID-19) IN INDIA. Asian Journal of Advances in Medical Science, 3(1), 44–52. Retrieved from


Download data is not yet available.


Perlman S. Another Decade, Another coronavirus. N Engl J Med; 2020.

Available: NEJMe2001126 PMID: 31978944.

Wang C. et al. A novel coronavirus outbreak of global health concern. Lancet; 2020.


Guan W. j. et al. Clinical characteristics of coronavirus disease 2019 in China. New England Journal of Medicine. 2020;382(18):1708-1720.

Guan WJ. et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med; 2020.


Chen H. et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet. 2020;395(10226):809–15.


Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020;395(10223):507-513.

Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat. Rev. Immunol. 2020;20:529−536.

Bhatraju PK. et al. Covid-19 in critically ill patients in the Seattle region—case series. New England Journal of Medicine; 2020.

Zhang W. et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9(1):386.


Van Doremalen N. et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med; 2020.


Li Q. et al. Early transmission dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med; 2020.


Yang Y. et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv; 2020.


Porcheddu R. et al. Similarity in case fatality rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125–8.


Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet; 2020.


Lu X. et al. SARS-CoV-2 Infection in Children. N Engl J Med; 2020.


Schmid MB et al. COVID-19 in pregnant women. Lancet Infect Dis; 2020.


Rouse BT, Sehrawat S. Immunity and immunopathology to Viruses: What Decides the Outcome? Nat. Rev. Immunol. 2010;10:514−526.

Klein SL, Jedlicka A, Pekosz A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010;10:338−349.

Zhao J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019, Clin. Infect. Dis; 2020.

DOI: 10.1093/cid/ciaa344.

Juno JA. et al. Humoral and circulating follicular helper T cell responses in recovered patients with COVID-19. Nat. Med. 2020;26:1428−1434.

Dhama K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccine Immunotherpy; 2020.


Ning et al. Subunit vaccines against emerging pathogenic human coronaviruses. Frontiers in Microbiology; 2020.

Available:https://doi. org/10.3389/fmicb.2020.00298.

Le Thanh T et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19: 305–6.

Le Tung. et al. The COVID-19 vaccine development landscape. Nature Reviews Drug Discovery. 2020;19(5):305–306.

Gupta V et al. SARS coronavirus nucleocapsid immunodominant T-cell epitope cluster is common to both exogenous recombinant and endogenous DNA-encoded immunogens. Virology. 2006;347(1):127–139.

Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;495–500.


COVID-19 vaccine. Vaccine information, ICMR New Delhi - COVID-19 Vaccine; 2020.


Panacea Biotec, Refana Announce Landmark Collaboration for Covid- 19 Vaccine. Panacea Biotec; 2020.


Mullard A. COVID-19 vaccine development pipeline gears up. The Lancet. 2020;395(10239):1751-1752.

Douglas RG, Samant VB. The vaccine industry. In: Plotkins SA, Orenstein WA, Offit PA, editors. Vaccine. 6th ed. China: Saunders Elsevier. 2013;33–43.

Lauer SA. et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Annals of internal medicine; 2020.